Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP002 in relapsed or refractory primary mediastinal large B-cell lymphoma
CTR20201901Phase 2Terminated
- Sponsor
- Taizhou Houde Aoke Technology
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LP002 in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Taizhou Houde Aoke Technology. Started Sep 2020; status: terminated.
02
Drugs
LP002
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on CTR20201901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201901.